Drug Trial Radar · NCT03768089
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
Last checked: Nov 19, 2026Latest source record: Jul 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Mar 20, 2018
Primary completion
May 3, 2019
Study completion May 3, 2019
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Dec 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis (CF).
Conditions
- Cystic Fibrosis
Interventions
Placebo (matched to VX-121 suspension)Drug
Placebo matched to VX-121 suspension for oral administration.
VX-121 (Suspension)Drug
Suspension for oral administration.
TEZ/IVADrug
Fixed-dose combination tablet for oral administration.
IVADrug
Tablet for oral administration.
Placebo (matched to TEZ/IVA)Drug
Placebo matched to TEZ/IVA for oral administration.
Placebo (matched to IVA)Drug
Placebo matched to IVA for oral administration.
VX-121 (Tablet)Drug
Tablet for oral administration.
Placebo (matched to VX-121 tablet)Drug
Placebo matched to VX-121 tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 Through Safety Follow-up (up to Day 15 for Part A [except Cohorts A3 and A9], up to Day 26 for Cohort A3, up to Day 34 for Cohort A9, up to Day 20 for Part B, up to Day 24 for Part C and up to Week 9 for Part D)
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Academic Medical Center
Amsterdam, Netherlands
PRA Health Sciences Onderzoekscentrum UMCG
Groningen, Netherlands
UMC St. Radboud
Nijmegen, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
HagaZiekenhuis van den Haag
The Hague, Netherlands
Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital
Birmingham, United Kingdom
The Medicines Evaluation Unit
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.